Published in Ann Surg on August 01, 2004
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol (2011) 2.10
Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics (2009) 2.03
Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol (2010) 1.82
A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. Obstet Gynecol (2014) 1.52
Can the new RCP R0/R1 classification predict the clinical outcome in ductal adenocarcinoma of the pancreatic head? Langenbecks Arch Surg (2012) 1.49
Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer (2007) 1.44
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer (2011) 1.43
Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol (2005) 1.37
A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg (2013) 1.36
Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) (2007) 1.26
Conditional Survival in Rectal Cancer: A SEER Database Analysis. Gastrointest Cancer Res (2007) 1.21
Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg (2010) 1.19
A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One (2012) 1.15
N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. J Gastrointest Surg (2012) 1.09
A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford) (2009) 1.07
Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg (2007) 1.04
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol (2011) 1.02
A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford) (2012) 1.02
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol (2011) 0.99
Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford) (2012) 0.98
Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg (2012) 0.98
Mitochondrial DNA depletion induces radioresistance by suppressing G2 checkpoint activation in human pancreatic cancer cells. Radiat Res (2009) 0.93
A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med (2014) 0.92
Pancreaticoduodenectomy can be safely performed in the elderly. Surg Today (2012) 0.89
Prognostic factors in periampullary and pancreatic tumor resection in elderly patients. World J Surg (2006) 0.86
Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg (2010) 0.86
Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford) (2009) 0.86
Validation of a prognostic nomogram in patients undergoing resection for pancreatic ductal adenocarcinoma in a UK tertiary referral centre. HPB (Oxford) (2008) 0.85
Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma. BMC Cancer (2014) 0.85
Conditional survival in pancreatic cancer: better than expected. HPB (Oxford) (2011) 0.84
Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study. Eur J Cancer (2015) 0.83
An interactive Bayesian model for prediction of lymph node ratio and survival in pancreatic cancer patients. J Am Med Inform Assoc (2014) 0.83
Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. World J Surg Oncol (2015) 0.82
Evaluation of peri-operative chemotherapy using a prognostic nomogram for survival after resection of colorectal liver metastases. HPB (Oxford) (2009) 0.82
Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst (2013) 0.82
Long-term survival in patients with pancreatic ductal adenocarcinoma. Surgery (2016) 0.81
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer (2014) 0.81
Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score. HPB (Oxford) (2013) 0.80
Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. Biomed Eng Online (2014) 0.78
Pancreas cancer survival in the gemcitabine era. Clin Med Oncol (2008) 0.78
Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver (2013) 0.77
Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Radiat Oncol (2011) 0.77
Prognostic estimator of survival for patients with localized and extended pancreatic ductal adenocarcinoma. Cancer Inform (2013) 0.77
High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. J Histochem Cytochem (2012) 0.77
External validation of two nomograms for predicting patient survival after hepatic resection for metastatic colorectal cancer. World J Surg (2011) 0.77
Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer. Ann Surg Oncol (2014) 0.77
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma. Int J Clin Exp Pathol (2012) 0.77
Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) (2011) 0.76
The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery. HPB (Oxford) (2014) 0.76
Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors (2013) 0.75
McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma. World J Gastroenterol (2014) 0.75
Design of a Global Medical Database which is Searchable by Human Diagnostic Patterns. Open Med Inform J (2008) 0.75
Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World J Surg Oncol (2015) 0.75
Timing of elective surgery as a perioperative outcome variable: analysis of pancreaticoduodenectomy. HPB (Oxford) (2013) 0.75
Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma. HPB (Oxford) (2015) 0.75
Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis. Med Oncol (2016) 0.75
Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head? HPB (Oxford) (2013) 0.75
A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio. HPB (Oxford) (2016) 0.75
Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis. J Cancer (2017) 0.75
Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients. Oncol Lett (2017) 0.75
Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Onco Targets Ther (2017) 0.75
A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Med (2017) 0.75
Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbecks Arch Surg (2016) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg (1993) 6.15
Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg (1996) 4.51
Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol (2002) 3.60
Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology (2001) 1.76
Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg (1998) 1.45
Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg (2001) 1.38
Randomized clinical trials in pancreatic cancer. Surg Oncol Clin N Am (2002) 1.30
Long-term survival following pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas. Surg Clin North Am (1995) 1.00
International network of cancer genome projects. Nature (2010) 20.35
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Against diagnosis. Ann Intern Med (2008) 3.69
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 2.69
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2008) 2.57
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology (2005) 2.49
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol (2008) 2.39
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol (2005) 2.30
Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. J Urol (2006) 2.30
The value of splenic preservation with distal pancreatectomy. Arch Surg (2002) 2.27
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18
Meta-analysis: Its strengths and limitations. Cleve Clin J Med (2008) 2.15
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst (2003) 2.11
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2004) 2.01
Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res (2008) 1.96
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol (2002) 1.88
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer (2002) 1.85
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol (2005) 1.83
Adenocarcinoma of the duodenum: importance of accurate lymph node staging and similarity in outcome to gastric cancer. Ann Surg Oncol (2004) 1.82
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol (2009) 1.81
Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care (2008) 1.81
An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med (2007) 1.80
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol (2002) 1.78
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol (2006) 1.73
Prostate cancer nomograms: an update. Eur Urol (2006) 1.71
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int (2007) 1.71
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer (2008) 1.70
Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys (2007) 1.69
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol (2009) 1.69
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg (2005) 1.64
Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology (2005) 1.63
Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol (2007) 1.63
Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol (2008) 1.61
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol (2007) 1.60
Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol (2008) 1.60
Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials (2007) 1.58
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol (2007) 1.57
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol (2004) 1.55
The association of community health indicators with outcomes for kidney transplant recipients in the United States. Arch Surg (2012) 1.53
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52
A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. Obstet Gynecol (2014) 1.52
Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. J Gastrointest Surg (2003) 1.49
Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecol Oncol (2012) 1.48
Nomogram to predict seminal vesicle invasion using the status of cancer at the base of the prostate on systematic biopsy. Int J Urol (2010) 1.47
Does mechanical bowel preparation ameliorate damage from rectal injury in radical prostatectomy? Analysis of 151 rectal injury cases. Int J Urol (2013) 1.47